Navigation Links
NEURO-BIOTECH DISCLOSES ITS LIST OF LICENSES
Date:9/28/2010

BASEL, Switzerland, Sept. 28 /PRNewswire-FirstCall/ - Neuro-Biotech Corporation (PINKSHEETS: MRES) (OTCQB: MRES) discloses its list of licenses.

NEURO # 1

SymPath(R)

TO EVALUATE THE SYMPATHETIC NERVOUS SYSTEM THROUGH THE ENZYME, DOPAMINE Beta- HYDROXYLASE (DBH), THAT IS RELEASED WITH NORADRENALINE WITHIN THE BLOOD AND DISTINGUISH BETWEEN DEPRESSIVE STATES AND ANXIOUS DISORDERS.

NEURO # 2

AXIS(TM)

TO QUANTITATIVELY AND DIRECTLY EVALUATE THE HYPOTHALAMO-PITUITARY ADRENAL AXIS THROUGH ENDING MOLECULES FORMED FROM THE RELEASED ACTH WITHIN THE BLOOD AND ACTING ON DESMOLASE ENZYME ACTIVITY, REQUIRING CHOLESTEROL BIOAVAILABILITY.

NEURO # 3

TETRIC(TM)

TO UNDERSTAND THE RELATIONSHIP BETWEEN CONSTITUTIVE & INDUCTIVE DBH ENZYME IN ORDER TO DISCRIMINATE PSYCHOAFFECTIVE AND MENTAL DISTURBANCES, THROUGH SIEVING MOLECULAR WEIGHT.

NEURO #4 and #5

ARE ONE PLATFORM FOR ALL OF THEM: 5-HT / 5HIAA DA / DOPAC / HVA NA / VMA / A MELATONIN TO UNDERSTAND THE RELATIONSHIP BETWEEN NEUROTRANSMITTERS, THE TURNOVER OF THEIR METABOLITES, AND TO FIGURE OUT THE CLINICAL PREDOMINENCE

NEURO # 6

TRYPTYR

TO EVALUATE THE BIOAVAILIBILITY OF TWO MAIN NEURO-TRANSMITTERS SUBSTRATES AND THEIR IMPACT IN BRAIN 5-HT AND NA SYNTHESIS.

NEURO #7

DIVAN

TO EVALUATE THE BIOAVAILABILITY OF THE EIGHT (8) ELECTROLYTES AND THEIR RELATIONSHIPS INVOLVED IN THE CNS.

NEURO # 8

GACHA

TO EVALUATE THE GABA AND ACETHYLCHOLINE RELATIONSHIP AT THE CELLULAR ENERGETIC CAPACITY.

NEURO # 9

FREERAD

TO MEASURE THE FREE RADICALS AND DETERMINE THEIR PREDOMINANCE IN REGARDS TO THE AXIS ACTIVITY.

NEURO # 10

MAOS

TO DETERMINE THE MAO TYPE A OR B ACTIVITY AND TO DEFINE THE CLINICAL PATIENT PROFILE IN RESPECT TO EXPECTED DIAGNOSIS AND THERAPEUTIC APPROACHES.

NEURO # 11

NEURENDOM

TO DEFINE THE MALE NEUROENDOCRINE PROFILE IN ORDER TO DIAGNOSE NEURO-PSYCHO-AFFECTIVE ENDOCRINE ILLNESS.

NEURO # 12

NEURENDOF

TO DEFINE THE FEMALE NEUROENDOCRINE PROFILE IN ORDER TO DIAGNOSE NEURO-PSYCHO-AFFECTIVE ENDOCRINE ILLNESS.


'/>"/>
SOURCE Neuro-Biotech Corp.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Neuro-Biotechs Solution for a Doctor near You: Early Detection for Alzheimers and Chronic Fatigue Syndrome!
2. Mr Claude Poulin nominated as President and CEO of Neuro-Biotech Corp.
3. AEterna Zentaris Discloses Preliminary Phase 2 Trial Results for Perifosine in Combination with Radiotherapy for Non-Small Cell Lung Cancer
4. New York State Licenses Personalized Prescribing DNA Tests
5. OvaGene Oncology Licenses Gene-Based Technologies to Develop Novel Endometrial and Cervical Cancer Assays
6. Ascenta Therapeutics Licenses Cancer Drug Candidates to sanofi-aventis
7. Transgenomic Licenses IP From IntegraGen to Develop Genetic Test for Autism
8. Cumberland Pharmaceuticals Licenses Caldolor(R) (ibuprofen) Injection to DB Pharm Korea for Commercialization in South Korea
9. Eidogen-Sertanty Licenses TIP to the FDA
10. Global Med Technologies(R), Inc. Licenses EdgeLab to Seven Laboratories at University Hospital of Reims, France
11. GeneGo Licenses MetaCore to Proteostasis Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... , March 22, 2017  UBM and the ... announce their extended partnership and the third annual Massachusetts ... by the 21 st Annual MassMEDIC Conference ... place May 3-4, 2017. MassMEDIC ... Association (ADVAMED) President and CEO, Scott Whitaker ...
(Date:3/22/2017)... , March 22, 2017 Oramed ... ( www.oramed.com ), a ... oral drug delivery systems, announced today that Dr. ... will deliver a presentation titled, "Oral Insulin for ... Cambridge Healthtech Institute,s Oligonucleotide and Peptide Therapeutics (OPT) ...
(Date:3/22/2017)... , March 22, 2017 ... fragmented, states a research report by Transparency Market Research ... Inc., Amgen Inc., and AbbVie Inc., accounted for a ... The prominent players in this market are focusing aggressively ... product portfolio, which is likely to lead to market ...
(Date:3/22/2017)... /PRNewswire/ - FACIT announced a seed stage investment ... start-up created by FACIT focused on developing a ... with non-dilutive capital, achieves a targeted $3.0M financing ... Propellon to accelerate the nomination of a candidate ... entering a strategic partnership for clinical trials in ...
Breaking Biology Technology:
(Date:3/2/2017)... Australian stem cell and regenerative medicine company, ... an agreement with the Monash Lung Biology Network, a ... and Department of Pharmacology at Monash University, ... to support the use of Cymerus™ mesenchymal stem cells ... Asthma is a chronic, long term lung condition recognised ...
(Date:2/28/2017)... 28, 2017 News solutions for biometrics, bag ... ... from 14 to 16 March, Materna will present its complete ... seamless travel is a real benefit for passengers. To accelerate ... their passenger touch point solutions to take passengers through the complete ...
(Date:2/26/2017)... Feb. 25, 2017  Securus Technologies, a leading ... for public safety, investigation, corrections and monitoring, announces ... Reentry. "Too often, too many offenders ... county jails are trying to tackle this ongoing ... friends and family members. While significant steps are underway, ...
Breaking Biology News(10 mins):